首页 | 官方网站   微博 | 高级检索  
     

藏药抗肝癌活性研究
引用本文:郑思建,徐 婵,杨 洁,黄 蕴,文琰章,宋 萍,林亲雄,王 强,杨新洲.藏药抗肝癌活性研究[J].华中师范大学学报(自然科学版),2017,51(3):328-334.
作者姓名:郑思建  徐 婵  杨 洁  黄 蕴  文琰章  宋 萍  林亲雄  王 强  杨新洲
作者单位:1.中南民族大学 药学院, 武汉 430074; 2.华中科技大学 同济医学院附属同济医院 药学部, 武汉 430000;3.青海民族大学 科学科技处, 西宁 810007
摘    要:本实验采用快速溶剂萃取法制备收集100种常用藏药的环己烷、乙酸乙酯和甲醇提取物,并运用MTT法对两个肝癌细胞株HepG2和SMMC-7721进行各提取物的抗肝癌活性测试,同时选用L-02细胞来评价其体外毒性.抗肝癌活性结果显示100种常用藏药中17种藏药材有良好的抗肝癌活性,其IC50值均小于150 μg/mL,其中马兜铃、蓝翠雀花、甘青青兰、掌叶橐吾的乙酸乙酯提取物显示出显著的抗肝癌活性,其IC50值均小于50 μg/mL,但马兜铃乙酸乙酯提取物对正常肝细胞L-02显示出一定的毒性.在进一步的抗HepG2肝癌活性验证中,结果显示蓝翠雀花乙酸乙酯提取物和甘青青兰乙酸乙酯提取物具有显著的抗肝癌活性,两者在抗HepG2肝癌细胞株活性中皆显示出显著的时效和量效关系.运用倒置显微镜以及Hoechst 33258荧光染色法对经过蓝翠雀花乙酸乙酯提取物或甘青青兰乙酸乙酯提取物作用的HepG2细胞形态进行观察,结果提示蓝翠雀花和甘青青兰乙酸乙酯提取物可能是通过诱导HepG2细胞凋亡而显示抗癌活性.

关 键 词:原发性肝癌    藏药    抗肝癌活性筛选    MTT    快速溶剂萃取  
收稿时间:2017-06-21

In vitro anticancer screening of Tibetan medicines
ZHENG Sijian,XU Chan,YANG Jie,HUANG Yun,WEN Yanzhang,SONG Ping,LIN Qinxiong,WANG Qiang,YANG Xinzhou.In vitro anticancer screening of Tibetan medicines[J].Journal of Central China Normal University(Natural Sciences),2017,51(3):328-334.
Authors:ZHENG Sijian  XU Chan  YANG Jie  HUANG Yun  WEN Yanzhang  SONG Ping  LIN Qinxiong  WANG Qiang  YANG Xinzhou
Affiliation:1.College of Pharmacy, South-Central University for Nationalities, Wuhan 430074;2.Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000;3.Division of Science & Technology, Qinghai University for Nationalities, Xining 810007
Abstract:The extraction of cyclohexane, ethyl acetate and methanol from 100 commonly used Tibetan medicines was prepared by the accelerated solvent extraction method. The MTT method was used to test antitumor activity of these 100 tibetan medicines against two hepatocellular carcinoma cell lines HepG2 and SMMC-7721, while preliminary toxicity towards normal human cells was investigated using a human liver cell line L-02. The antitumor screening results showed that 17 tibetan medicines exhibited antitumor activities against HepG2 and SMMC-7721 with IC50 values less than 150 μg/mL. Among them, the ethyl acetate extracts of Aristolochia impresinervis, Delphinium caeruleum, Dracocephalum tanguticum and Ligularia przewalskii showed significant antitumor activity against HepG2 and SMMC-7721 with IC50 values less than 50 μg/mL, but tthat of Aristolochia impresinervis showed certain toxicity against L-02 up to 200 μg/mL. In the further validation of anti-HepG2 liver cancer activity, the results signified that the ethyl acetate extracts of Delphinium caeruleum and Dracocephalum tanguticum had significant anti-hepatocarcinoma activities, both of which presented significant time and dose dependent relationships against HepG2 hepatocarcinoma cell lines. The morphological changes of HepG2 cells treated with the ethyl acetate extracts of Delphinium caeruleum or Dracocephalum tanguticum were investigated by inverted microscope and Hoechst 33258 fluorescent staining method. The results demonstrated that apoptosis were induced by the ethyl acetate extracts of Delphinium caeruleum and Dracocephalum tanguticum anti-cancer in HepG2 cells.
Keywords:primary hepatocellular carcinoma  Tibetan medicines  anti-cancer screening  MTT  accelerated solvent extracting  
本文献已被 CNKI 等数据库收录!
点击此处可从《华中师范大学学报(自然科学版)》浏览原始摘要信息
点击此处可从《华中师范大学学报(自然科学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号